Health Care • Biotechnology: Laboratory Analytical Instruments
$6.30 ▲ +0.16
(+2.61%)
MKT CAP: $818.9M • VOL: 1.91M
52W L $3 52W H $6
CTKB // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $201.5M | $200.5M | $193.0M |
| YoY Revenue Growth % | +0.5% | +3.9% | — |
| Gross Profit | $104.5M | $111.1M | — |
| Gross Margin % | 51.8% | 55.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$40.4M | -$20.5M | -$27.8M |
| Operating Margin % | -20.0% | -10.2% | -14.4% |
| Net Income (GAAP) | -$66.5M | -$6.0M | -$12.1M |
| EBITDA (Normalized) | -$37.1M | -$17.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.7M | $25.4M | $5.3M |
| Capital Expenditures (CapEx) | $4.1M | $3.5M | — |
| Free Cash Flow (FCF) | -$8.8M | $21.9M | $5.3M |
| FCF Margin % | -4.4% | 10.9% | 2.7% |
| Return on Invested Capital (ROIC %) | -12.7% | -5.5% | — |
| Cash & Short-Term Equivalents | $90.9M | $98.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $341.7M | $395.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CTKB.